Klaria Interim Report Q1 2022

Klaria Interim Report Q1 2022

Summary of the Interim Report

First quarter of 2022

- Net sales amounted to 0.0 MSEK (0.0 MSEK)

- R&D costs for the period amounted to 17.1 MSEK (11.4 MSEK)

- Profit after tax amounted to -20.3 MSEK (-16.7 MSEK)

- Earnings per share for the quarter amounted to -0.37 SEK (0.32 SEK)

- Cash flow from operating activities amounted to -19.8 MSEK (17.1 MSEK)

- Cash and cash equivalents on the balance sheet date amounted to 23.0 MSEK (48.2 MSEK)

- Equity as of March 31 amounted to 72.1 MSEK (126.3 MSEK)

- Pursuant to the authorization granted by the Annual General Meeting on March 18, 2021, the Board decided on a directed share issue of a maximum of 5,750,000 shares with a subscription price of 4SEK per share, corresponding to a gross payment of no more than 23 MSEK before issue costs

- Klaria Pharmaceuticals signs agreement with FluiMed GmbH to develop Sirolimus Alginate Film for prevention of Organ Transplant Rejection

For more information, visit the  Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.